EP Patent

EP4079296A1 — A bilayer tablet formulation comprising amorphous dapagliflozin and metformin

Assigned to Sanovel Ilac Sanayi ve Ticaret AS · Expires 2022-10-26 · 4y expired

What this patent protects

The invention relates to a bilayer tablet comprising metformin in the form of the free base or in the form of pharmaceutically acceptable salts, crystalline polymorph thereof and amorphous dapagliflozin, and at least one pharmaceutically acceptable excipient, wherein the tablet i…

USPTO Abstract

The invention relates to a bilayer tablet comprising metformin in the form of the free base or in the form of pharmaceutically acceptable salts, crystalline polymorph thereof and amorphous dapagliflozin, and at least one pharmaceutically acceptable excipient, wherein the tablet is free of magnesium stearate. Also, the combination has an immediate release layer and an extended release layer.

Drugs covered by this patent

Patent Metadata

Patent number
EP4079296A1
Jurisdiction
EP
Classification
—
Expires
2022-10-26
Drug substance claim
No
Drug product claim
No
Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.